ライフサイエンスコーパス: menopause

1 wed later by ovariectomy (OVX; as a model of menopause).

2 elatively late), and 55 years or older (late menopause).

3 food intake is associated with risk of early menopause.

4 p in 1991 were followed until 2011 for early menopause.

5 skeletal fragility that operate long before menopause.

6 opause and 644 (0.4%) had surgical premature menopause.

7 communities in a rat model that mimics human menopause.

8 le) in relation to the number of years since menopause.

9 hat are unmasked by loss of estradiol during menopause.

10 previously been investigated in relation to menopause.

11 apacity, known as the ovarian reserve, until menopause.

12 of pubertal onset, hormone levels and age at menopause.

13 woman's reproductive lifespan, resulting in menopause.

14 ce arteries were attenuated by aging and the menopause.

15 nce subjective executive difficulties during menopause.

16 er and nonsignificant for surgical premature menopause.

17 the increased cardiovascular risk of earlier menopause.

18 subgroups or by timing of intervention after menopause.

19 destly associated with a lower risk of early menopause.

20 nd FEV1, is accelerated in women who undergo menopause.

21 s and how they may be altered with aging and menopause.

22 aused by a withdrawal effect of oestrogen at menopause.

23 y and secondary amenorrhoea as well as early menopause.

24 focusing on behaviors that are modifiable at menopause.

25 n and did not have breast cancer or surgical menopause.

26 omen who experience premature or early-onset menopause.

27 in the aging process, as they transition to menopause.

28 parity, lower PCOS risk, and earlier age at menopause.

29 pause and 887 (4.5%) with surgical premature menopause.

30 ze of the oocyte pool and thus the timing of menopause.

31 when it was initiated 10 or more years after menopause.

32 wer chronic systemic inflammation even after menopause.

33 sexual dimorphism declines with the onset of menopause.

34 women with a lower incidence in women before menopause.

35 was incidence of chemotherapy-induced early menopause.

36 was significantly associated with premature menopause.

37 a for subsequent malignancies and the age at menopause.

38 ts except MTX-FA increased the risk of early menopause.

39 GRS1 for age at menarche and GRS2 for age at menopause.

40 ted in pregnancy and one who presented after menopause.

41 t hormone measures and experienced a natural menopause.

42 risk for breast cancer, especially prior to menopause.

43 verse normal AMH per one-year earlier age at menopause.

44 my and women who did not report their age at menopause.

45 for species management and the evolution of menopause.

46 ry-food intake was not associated with early menopause.

47 pausal women was shown for increasing age at menopause (0.98; 0.96-0.99 [67,434 unique participants;

48 pression revealed similar results for age at menopause (0.98; 0.96-1.00 [48,894 unique participants;

49 use (HR 1.88, 1.62-2.20; p<0.0001) and early menopause (1.40, 1.27-1.54; p<0.0001), but were attenuat

50 uctive helping could in principle select for menopause [1, 2, 5], but the magnitude of these benefits

51 n were diagnosed with AAA, 134 had premature menopause (11.9%), 93 underwent surgical intervention an

52 se 43.7 +/- 8.6 years), women with premature menopause (29.3%) were younger at enrollment (P < 0.001)

53 000 woman-years) (difference vs no premature menopause, +3.08/1000 woman-years [95% CI, 2.06-4.10]; P

54 menopausal, younger than 40 years (premature menopause), 40-44 years (early menopause), 45-49 years (

55 Among the participants (age at menopause 43.7 +/- 8.6 years), women with premature meno

56 rs (premature menopause), 40-44 years (early menopause), 45-49 years (relatively early), 50-51 years

57 000 woman-years) (difference vs no premature menopause, +5.57/1000 woman-years [95% CI, 2.41-8.73]; P

58 on with increasing (2-year increment) age at menopause (52,736 unique participants; 3 studies); sensi

59 ppears insufficient to explain the timing of menopause [6-8].

60 Risk factors that are modifiable at menopause account for more than one-third of postmenopau

61 ced risk of cardiovascular disease following menopause after age 51 years (p<0.0001 for trend).

62 tenuation compared with men (P < .008) until menopause, after which both groups had similar values.

63 isease was higher in women who had premature menopause (age <40 years; HR 1.55, 95% CI 1.38-1.73; p<0

64 HR 1.55, 95% CI 1.38-1.73; p<0.0001), early menopause (age 40-44 years; 1.30, 1.22-1.39; p<0.0001),

65 , 1.22-1.39; p<0.0001), and relatively early menopause (age 45-49 years; 1.12, 1.07-1.18; p<0.0001),

66 We estimated LOY as age at menopause (age at blood collection for premenopausal wom

67 ted lifetime ovulatory years (LOY) as age at menopause (age at blood collection for premenopausal wom

68 The associations of premature menopause (age at menopause of <40 years) and time from

69 age at menopause of <40 years) and time from menopause (age at study enrollment - age at menopause, y

70 Excluding WWH with surgical menopause, age at final menstrual period was summarized

71 occurring before adulthood in 11,781 cases (menopause aged under 45) and 173,641 controls (menopause

72 sociations were larger for natural premature menopause (all CHIP: odds ratio, 1.73 [95% CI, 1.23-2.44

73 r these conditions that can be attributed to menopause alone is uncertain.

74 iable risk factor for reducing risk of early menopause among premenopausal women.

75 e analyzed PFOA in relation to self-reported menopause among women (n = 9,192) 30-65 years old and in

76 Additional research on age at menopause among WWH is needed.

77 er 10,000 (9.4%) women experienced premature menopause and 22,240 (22%) experienced early menarche.

78 4] years), 4904 (3.4%) had natural premature menopause and 644 (0.4%) had surgical premature menopaus

79 including 418 (2.1%) with natural premature menopause and 887 (4.5%) with surgical premature menopau

80 Hormonal changes during menopause and andropause impact the processes of memory

81 improving quality of sleep in patients with menopause and could have a long-lasting effect.

82 ed to discuss the contemporary literature on menopause and CVD risk with the intent of increasing awa

83 aluation or validated instruments, by age at menopause and duration of the reproductive period.

84 ies evaluating the effect of age at onset of menopause and duration since onset of menopause on inter

85 nalling could inhibit hot flushes during the menopause and during treatment for sex-steroid dependent

86 sex-specific risk factors, such as premature menopause and early menarche, with risk of AAA in a larg

87 Menopause and eGFR were significantly associated with me

88 5% CI 1.15-1.61; P = 0.0003); age at natural menopause and endometrioid carcinoma (OR per year later

89 iated with MHT in women experiencing natural menopause and for late age at natural menopause warrant

90 considered natural versus surgical premature menopause and gene-specific CHIP subtypes.

91 e risk include HDP for ischemic stroke, late menopause and gestational hypertension for hemorrhagic s

92 Menopause and hormone status accounted for some, but not

93 ovarian failure, reducing the risk of early menopause and improving prospects for fertility.

94 sess the associations between age at natural menopause and incidence and timing of cardiovascular dis

95 lity; however, the association between early menopause and incidence and timing of cardiovascular dis

96 95% CIs for the associations between age at menopause and incident cardiovascular disease event.

97 ogenous estrogens, expressed as older age at menopause and longer reproductive period, is associated

98 the individual risk factors, such as ages at menopause and menarche.

99 riectomized-osteoporosis rats were used as a menopause and menopause-osteoporosis model, respectively

100 ped by transitional periods such as puberty, menopause and pregnancy, while daily fluctuations in mic

101 conjecture that in previous studies, earlier menopause and reduced kidney function are the causes rat

102 AMH decreased markedly before menopause and remained low subsequently.

103 no significant association between premature menopause and risk of AAA amongst women who have never s

104 Johnstone and Cant introduce menopause and the phenomenon of an extended post-reprodu

105 We assessed the associations of age at menopause and time from menopause with fibrosis severity

106 increase in the risk for this disease after menopause and typically develop coronary heart disease s

107 en women between 50 and 54 years at onset of menopause and women younger than 50 years at onset; ther

108 oss-sectional) that assessed age at onset of menopause and/or time since onset of menopause as exposu

109 ctional studies; reported on age at onset of menopause and/or time since onset of menopause as exposu

110 rding to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use.

111 re used to evaluate the associations of sex, menopause, and hormone status with biomarkers.

112 ted to a modifying effect of age, time since menopause, and HT formulation.

113 being premenopausal, having an older age at menopause, and never taking HRT, both in cases and contr

114 and age at first and last live birth, age at menopause, and postmenopausal hormone use.

115 n) and ovariectomized (induction of surgical menopause) animals that show reduced Runx2 and enhanced

116 P2L locus are associated with age at natural menopause (ANM).

117 ing variation associated with age at natural menopause (ANM).

118 ogically impactful events of parturition and menopause are recorded in dental cementum microstructure

119 rations, other dairy constituents, and early menopause are warranted.

120 ductive features, e.g., ages at menarche and menopause, are found to be associated with endometrial c

121 Menopause as a result of ovarian follicle depletion is t

122 nset of menopause and/or time since onset of menopause as exposures as well as risk of cardiovascular

123 nset of menopause and/or time since onset of menopause as exposures; and assessed associations with r

124 hytoestrogen-rich soy is known to ameliorate menopause-associated obesity and metabolic dysfunction f

125 sing their reproduction and/or going through menopause (assuming that these traits are easier to sele

126 Menopause at age 40 or more years compared with prematur

127 Compared with women who had menopause at age 50-51 years, the risk of cardiovascular

128 Compared with women who had menopause at age 50-51 years, women with premature and e

129 were 2.24 (95% CI, 1.19-4.21) in women with menopause at the age of at least 55 years vs 50 to 54 ye

130 Among women who were less than 6 years past menopause at the time of randomization, the mean CIMT in

131 Among women who were 10 or more years past menopause at the time of randomization, the rates of CIM

132 ons of recent models [5] of the evolution of menopause based on kinship dynamics.

133 Natural premature menopause (menopause before age 40 without oophorectomy) and surgic

134 Recent guidelines endorse using history of menopause before age 40 years to refine atherosclerotic

135 on-years, 2041 women reported having natural menopause before the age of 45 y.

136 Natural and surgical premature menopause (before age 40 years) were associated with a s

137 without oophorectomy) and surgical premature menopause (bilateral oophorectomy before age 40).

138 the therapy is initiated temporally close to menopause but not when it is initiated later.

139 n therapy was initiated within 6 years after menopause but not when it was initiated 10 or more years

140 nt of fecal incontinence (FI) in women after menopause by altering neuromuscular continence mechanism

141 : As many as 10% of women experience natural menopause by the age of 45 years.

142 In theory, menopause can evolve via inclusive fitness benefits [5,

143 Declines in endogenous estrogen levels after menopause can lead to systemic bone loss, including loss

144 ic, child, and biomedical (e.g., medication, menopause, CGG repeats) factors.

145 through January 1, 2015) using the key terms menopause, climacteric, reproductive period, depression,

146 hat has been previously shown to mimic human menopause compared to sham-operated (SHM) intact control

147 3) and 1.06 (95% CI: 0.87, 1.30) >=5 y after menopause compared with 0.50 (95% CI: 0.31, 0.81) in pre

148 ty associated with premature and early-onset menopause could be an important factor affecting risk of

149 ew that grandmother effects alone select for menopause coupled with long post-reproductive lifespan.

150 Alterations in hormone levels during menopause decrease bone density and may worsen oral heal

151 Early menopause, defined as the cessation of ovarian function

152 tment for weight, height, physical activity, menopause duration, calcium intake, and the interaction

153 Similarly, age at menopause, endometriosis, and tubal ligation were only a

154 Premature menopause, especially natural premature menopause, is in

155 g 25 years of follow-up, 1,045 women reached menopause (for NM, n = 588; for HOC, n = 304; and for HB

156 l women experience genitourinary syndrome of menopause, for which many use lubricating vaginal produc

157 Women who had undergone surgical menopause had a 51% higher risk of B-cell NHL (based on

158 50-51 years, women with premature and early menopause had a substantially increased risk of a non-fa

159 The genitourinary syndrome of menopause has a negative impact on quality of life of po

160 Few modifiable risk factors for early menopause have been identified, but emerging data sugges

161 rs, longitudinal studies of women traversing menopause have contributed significantly to our understa

162 was associated with 23% lower risk of early menopause (hazard ratio = 0.77, 95% confidence interval:

163 (based on 67 cases) than women with natural menopause (hazard ratio = 1.51, 95% confidence interval:

164 BCC was associated with late age at natural menopause (hazard ratio [HR] for >/= 55 years v 50 to 54

165 before age 60 years for women with premature menopause (HR 1.88, 1.62-2.20; p<0.0001) and early menop

166 borderline significantly lower risk of early menopause (HR: 0.87; 95% CI: 0.76, 1.00; P-trend = 0.03)

167 parity, age at first and last births, age at menopause, hysterectomy, oophorectomy, hormone therapy u

168 orted their menopause status, age at natural menopause (if postmenopausal), and cardiovascular diseas

169 were able to detect reproductive events and menopause in all females.

170 idual dairy foods were associated with early menopause in Nurses' Health Study II.

171 Time since onset of menopause in relation to risk of developing intermediate

172 hese boutons form are altered with aging and menopause in rhesus monkeys and that these metrics may b

173 m are associated with the incidence of early menopause in the prospective Nurses' Health Study II (NH

174 size the challenge in determining definitive menopause in women with chemotherapy-induced amenorrhea.

175 and 49 women (7.6%) with surgical premature menopause (incidence, 11.27/1000 woman-years) (differenc

176 urred in 5415 women (3.9%) with no premature menopause (incidence, 5.70/1000 woman-years), 292 women

177 rs), 292 women (6.0%) with natural premature menopause (incidence, 8.78/1000 woman-years) (difference

178 ing, but decreased by over 50% with surgical menopause induced by ovariectomy in aged monkeys.

179 n, reductions in circulating oestrogens with menopause interact with ageing processes to induce vascu

180 Loss of estrogens at menopause is a major cause of osteoporosis and increased

181 Menopause is an important physiological stage in women's

182 Premature menopause is an independent risk factor for cardiovascul

183 Menopause is associated with bone loss and enhanced visc

184 RATIONALE: Menopause is associated with changes in sex hormones, wh

185 Whether premature menopause is associated with CHIP is unknown.

186 Furthermore, genetic susceptibility to later menopause is associated with higher PCOS risk (P=1.6 x 1

187 Hormone therapy after menopause is controversial.

188 years, and the average US woman who reaches menopause is expected to live another 30 years.

189 Early menopause is linked to an increased risk of cardiovascul

190 omen may suggest that decreased oestrogen at menopause is partially responsible for the gender-relate

191 served association between measured PFOA and menopause is subject to reverse causation for this outco

192 Earlier age at menopause is widely considered to be associated with an

193 ture menopause, especially natural premature menopause, is independently associated with CHIP among p

194 s of protracted childhood and prolonged post-menopause longevity as derived human characteristics.

195 omen were stratified according to time since menopause (<6 years [early postmenopause] or >/=10 years

196 This study finds that premature menopause may be an important risk factor for AAA in wom

197 Natural premature menopause may serve as a risk signal for predilection to

198 oup analyses by age, age at menarche, age at menopause, menopausal status, number of pregnancies, bre

199 Natural premature menopause (menopause before age 40 without oophorectomy)

200 monitoring in clinical practice, and age at menopause might also be considered as an important facto

201 e hypothesis that the decline of estrogen at menopause might contribute to the pathogenesis of HFpEF

202 However, after menopause, NAFLD occurs at a higher rate in women, sugge

203 Women with earlier menopause need close monitoring in clinical practice, an

204 cular disease (CVD) before and after natural menopause (NM), hysterectomy with at least 1 ovary conse

205 at menarche, first and last live birth, and menopause; number of live births; hormonal contraceptive

206 menopause was defined as natural or surgical menopause occurring before age 40 years.

207 Menopause occurs at a median age of 51.3 years, and the

208 ple birth was strongly associated with early menopause (odds ratio = 1.42, confidence interval: 1.11,

209 associations of premature menopause (age at menopause of <40 years) and time from menopause (age at

210 non-fatal cardiovascular disease event after menopause, of whom 9369 (3.1%) had coronary heart diseas

211 ed and conflicting evidence on the effect of menopause on asthma.

212 set of menopause and duration since onset of menopause on intermediate CVD end points, CVD outcomes,

213 investigated the influence of aging and the menopause on the acute vasodilatory effects of estrogen

214 When examined according to years since menopause onset (<10 years) rather than age group, resul

215 it can be expected to successfully bridge to menopause or allow for a less-invasive intervention.

216 ly determined as the period from menarche to menopause or lifetime number of ovulatory cycles after a

217 lifespan, roughly age of menarche to age of menopause or lifetime ovulatory cycles after accounting

218 alcium balance that developed in women after menopause or oophorectomy.

219 EMENT Estrogen replacement therapy following menopause or surgical removal of the ovaries is a widesp

220 ostmenopausal includes patients with natural menopause or that induced by ovarian suppression or abla

221 ncome, nativity, smoking, physical activity, menopause, oral contraceptive use, hormone therapy, and

222 orosis and ovariectomized rats as a model of menopause-osteoporosis and menopause women.

223 teoporosis rats were used as a menopause and menopause-osteoporosis model, respectively.

224 esus macaques, soon after surgically-induced menopause [ovariectomy (OVX)], on tests of memory and at

225 Older age at menopause (P = 0.007), earlier menarche (P = 0.007), and

226 Older age at menopause (p=0.007), earlier menarche (p=0.007), and sho

227 cline in ovarian estradiol production during menopause plays a significant role in shaping memory cir

228 nopause aged under 45) and 173,641 controls (menopause/pre-menopausal at >/= 45 years), in models con

229 symptoms and quality of life measured by the Menopause Quality of Life (Men-QoL), Insomnia Severity I

230 life, measured by the Greene Climacteric and Menopause Quality of Life scales.

231 The menopause rating score improved significantly in the And

232 s16991615, previously associated with age at menopause, reached genome-wide significance at P = 3.48

233 nonhuman primates are vulnerable to age- and menopause- related decline in working memory, a cognitiv

234 us monkeys and women are subject to age- and menopause-related deficits in working memory, an executi

235 .02, Cohen's d = 0.51), and improved overall menopause-related quality of life (- 2.53 [- 4.17; - 0.8

236 AMH-by chronological age and time around the menopause (reproductive age) in mid-life women and explo

237 Menopause results from loss of ovarian function and mark

238 Postmenopausal women without premature menopause served as the reference group.

239 Classic life-history theory predicts that menopause should not occur because there should be no se

240 Conclusion Negative changes in menopause-specific QOL influence a woman's decision to s

241 in any MENQOL domain or, especially, overall menopause-specific QOL, was associated with early treatm

242 stics and clinically meaningful worsening in menopause-specific quality of life (QOL) with treatment

243 ating exemestane, participants completed the Menopause-Specific Quality of Life Questionnaire (MENQOL

244 vestigated the association between worsening menopause-specific quality of life, baseline participant

245 Women who had reported their menopause status, age at natural menopause (if postmenop

246 amine the impact of patient factors (such as menopause status, body mass index, and vaginal pH) in th

247 sociation of SHBG with T2D did not change by menopause status, whereas the associations of ESH and T2

248 cess underlying PD symptoms may begin before menopause, suggests that estrogen-based hormone therapy

249 d) had a significant 17% lower risk of early menopause than women with the lowest intake [quintile me

250 Early natural menopause, the cessation of ovarian function prior to ag

251 Menopause timing has a substantial impact on infertility

252 the aging process, as women transition into menopause, to identify neuronal and cognitive changes th

253 the etiology of depression with onset in the menopause transition ("perimenopausal depression") invol

254 s observation led to the hypothesis that the menopause transition (MT) contributes to the increase in

255 ich the changing hormonal environment of the menopause transition may interact with the psychosocial

256 eport difficulties in this domain during the menopause transition.

257 ptoms increases two- to threefold during the menopause transition.

258 levels increased for the first 7 years after menopause (trend test, p < 0.0001), providing further ev

259 Menopause triggers changes in sexual function and many w

260 fication by age, body mass index, time since menopause, use of hormone replacement therapy, use of ca

261 ovariectomized (OVX) mice, a model of human menopause, using co-expression network analysis.

262 atural menopause and for late age at natural menopause warrant further investigation.

263 n with versus without a history of premature menopause was 8.8% versus 5.5% (P<0.001), respectively.

264 age 40 or more years compared with premature menopause was associated with a 50% decreased risk for d

265 Younger age at menopause was associated with a higher risk of DCIS but

266 , and hormone replacement therapy, premature menopause was associated with an increased likelihood of

267 Premature menopause was associated with increased risk of AAA [haz

268 association but genetically-predicted age at menopause was associated with lower AMH levels by 0.18 S

269 Age at natural menopause was categorised as premenopausal or perimenopa

270 Premature menopause was defined as natural or surgical menopause o

271 nterval 1.3-2.7, P = 0.001), while time from menopause was directly associated with an increased like

272 After multivariable adjustment, premature menopause was independently associated with CHIP (all CH

273 The cumulative risk of early menopause was low after MTX-FA but was substantial after

274 , hormonal use, diabetes and age at menarche/menopause was obtained for all individuals.

275 ea (which has been associated with premature menopause) was associated with a significantly lower ris

276 and (2) self-reported information on age at menopause were analyzed.

277 mary outcome, natural and surgical premature menopause were associated with hazard ratios of 1.36 (95

278 Impaired kidney function and earlier menopause were associated with perfluorooctanoic acid (P

279 Cases of incident early menopause were identified from all participants who were

280 Women with premature menopause were more likely to be overweight, Black, have

281 reproductive duration [time from menarche to menopause]) were self-reported at study baseline in 1993

282 oxidative shielding and revealed only after menopause when shielding has ceased.

283 ated with ovarian reserve, declining towards menopause when the oocyte pool is exhausted.

284 This sex difference is reversed at menopause, when women develop higher sympathetic nerve a

285 ssociation between multiple births and early menopause, which connects events pre-birth, when the ooc

286 A hallmark of menopause, which follows the decline in the ovarian prod

287 ory (n = 19,286), 2148 (11.1%) had premature menopause, which was associated with greater risk of AAA

288 of vitamin D and calcium and incident early menopause while accounting for potential confounding fac

289 n at higher risk for depression due to early menopause who could benefit from psychiatric interventio

290 most increased among women reporting natural menopause who used MHT for 10 or more years versus women

291 g of the mechanisms linking seizures and the menopause will help to develop effective therapeutic str

292 The potential association of menopause with carotid intima-media thickness as well as

293 gression tested the association of premature menopause with CHIP, adjusted for age, race, the first 1

294 hed men, but this advantage disappears after menopause with disrupted glucose homeostasis, in part ow

295 We analysed the association of early menopause with events occurring before adulthood in 11,7

296 sociations of age at menopause and time from menopause with fibrosis severity in postmenopausal women

297 ats as a model of menopause-osteoporosis and menopause women.

298 menopause (age at study enrollment - age at menopause, years) with fibrosis severity (stage 0-4) wer

299 onal associations were assessed for eGFR and menopause (yes/no).

300 were compared between women who experienced menopause younger than 45 years and women 45 years or ol